Keeping good diagnostics fast, minimal invasive and affordable is a main challenge in current health care; advanced diagnostic techniques in analytical chemistry pose a possible solution
Sylvia Genet is a PhD student working in the field of clinical chemistry with prof. dr. ir. Luc Brunsveld and prof. dr. Volkher Scharnhorst. Her project is based on a collaboration between the Laboratory of Chemical Biology at the TU/e and the clinical labs of the Catharina Hospital Eindhoven and Máxima Medical Center Eindhoven/Veldhoven. Her current research is focusing on the exploration of the clinical added value of protein biomarkers in diagnostics and monitoring of lung cancer and the development, validation and integration of a tandem mass spectrometry-based method for protein tumor marker analysis.
Sylvia Genet studied Biomedical Engineering at the TU/e and obtained her Bachelor of Science degree in 2016. During her Bachelor she participated in the international student competition ‘SensUs’, where she worked in an interdisciplinary student team to develop a biosensor for monitoring creatinine levels for the detection of kidney failure. After that, she started her Master in the Chemical Biology group of prof. dr. ir. Luc Brunsveld at the TU/e, where she performed her graduation project under the supervision of dr. Christian Ottmann in collaboration with the industrial partner AstraZeneca. During this project she focused on the development of small‑molecule modulators for the 14-3-3-YAP/TAZ protein-protein interactions. Hereafter she went to the pharmaceutical company UCB in Slough (UK) to work on a fragment-based drug discovery project for the exploration of new techniques to target protein-protein interactions. Sylvia obtained her Master of Science degree in 2018 and to learn more about biomedical engineering in a clinical setting, she started her PhD at the TU/e in collaboration with the Catharina hospital Eindhoven and Máxima Medical Center Eindhoven/Veldhoven under supervision of prof. dr. ir. Luc Brunsveld and prof. dr. Volkher Scharnhorst.
No ancillary activities